Boundless Bio (BOLD) Insider Kevin Tang Buys $363K of Stock

Kevin Tang has increased his stake in Boundless Bio, Inc. (NasdaqGS: BOLD) by purchasing 146,390 shares on June 25, 2026. The shares were bought at an average price of $2.48, totaling approximately $363,091. This move highlights Tang's continued interest in the biotechnology firm.

Insider Buying and Selling at Boundless Bio, Inc.

Kevin Tang has been actively buying shares of Boundless Bio, Inc., with transactions recorded on June 25, June 26, and June 29, 2026. On June 25, he acquired 146,390 shares at $2.48 each. Two additional purchases followed, with 75,181 shares bought at $2.55 on June 26, and 64,762 shares at $2.47 on June 29. Other insiders, including James Christensen, Jennifer Lew, and Nancy Whiting, also participated in purchasing shares on June 15, 2026.

Other Institutional Activity in Boundless Bio, Inc.

Several institutional investors have recently adjusted their holdings in Boundless Bio, Inc. FMR LLC increased its stake by 11,433 shares, ending with 2,695,455 shares valued at approximately $2.97 million. Citadel Advisors LLC trimmed its position by 11,773 shares, leaving it with 1,342,131 shares worth about $1.48 million. Sectoral Asset Management Inc held steady with 678,574 shares valued at $746,431. Meanwhile, Stonepine Capital Management, LLC reduced its holdings by 112,389 shares, now holding 597,682 shares worth $657,450. Vanguard Capital Management LLC opened a new position, acquiring 597,192 shares valued at around $656,911.

Boundless Bio, Inc. Stock Down 12.8%

On Tuesday, shares of Boundless Bio, Inc. (NasdaqGS: BOLD) traded near $2.56. The company has a market capitalization of approximately $57.5 million. Boundless Bio is not currently profitable, so it has no meaningful P/E ratio, but it maintains a forward P/E of -1.80. The stock's beta is 0.974, suggesting moderate volatility compared to the market. Over the past year, the stock has ranged from a low of $0.96 to a high of $2.79. Its 50-day moving average stands at $1.56, while the 200-day moving average is $1.29. The company's current ratio is a strong 9.87, with a quick ratio of 9.69 and a debt-to-equity ratio of 55.9.

Analysts Set New Price Targets

Analysts have been active in setting price targets for Boundless Bio, Inc. On August 11, 2025, HC Wainwright & Co. maintained a 'buy' rating with a $4.00 price target. Earlier, on June 2, 2025, they initiated coverage with a 'buy' rating and a $5.00 target. Meanwhile, Leerink Partners downgraded the stock to 'hold' with a $3.00 target on May 28, 2025.

About Boundless Bio, Inc.

Boundless Bio, Inc. is a clinical-stage biotechnology company based in San Diego, California. It focuses on developing therapies that target extrachromosomal DNA (ecDNA) to treat cancers with oncogene amplification. The company's lead candidate, BBI-940, is currently in Phase 1/2 clinical trials for certain types of breast cancer. Founded in 2018 and led by CEO Zachary D. Hornby, Boundless Bio employs 28 people and is part of the healthcare sector.

Bottom Line

Kevin Tang's recent purchase of Boundless Bio, Inc. shares underscores his confidence in the company's potential. The stock's recent trading activity and institutional movements reflect a dynamic interest in its future prospects. As a clinical-stage biotech firm, Boundless Bio is closely watched by investors for developments in its pipeline and market strategy. Keep in mind that insider transactions like these are reported after the fact and may not indicate future actions.